In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


COURAGE Trial: Bad News Again for Stents at ACC, Or Is It?

Executive Summary

For the second year in a row, results from a clinical trial announced at the annual American College of Cardiology (ACC) conference appeared to be bad news for coronary stents. The outcomes from the COURAGE trial, announced at this year's ACC meeting in New Orleans at the end of March, found that angioplasty with stenting did not reduce the risk of major adverse cardiovascular events when added to optimal medical therapy.

You may also be interested in...

Volcano Explodes in Therapy Guidance

In the world of medical devices, there are companies that begin by developing one thing and wind up doing something altogether different. But few have taken the kind of path that Volcano has. Once a high-flying dynamo with dreams of striking it big in vulnerable plaque, Volcano has seen those dreams all but disappear. But instead of crashing to earth Icarus-like, Volcano is soaring, this time on the back of the unlikeliest of technologies, intravascular ultrasound (IVUS), and a business built on a number of opportunistic commercial moves made while still forging ahead in vulnerable plaque. Volcano's new vision: that of a therapy-guidance leader, a "theranostic company," that helps physicians understand whom, how, and when best to treat.

Drug-Eluting Balloons: New Route to Revascularization

A few companies with the foresight, even during the heyday of drug-eluting stents, to begin developing drug-eluting balloons are well-positioned to capture one of the next enormous growth markets in cardiology, according to "Current and Emerging US Markets for Myocardial Revascularization, Repair, and Regeneration Products and Technologies," a report recently published by the Medtech Insight division of FDC-Windhover.

TCT Debates Cardiology's "Climate of Calamity"

The real story that came out of this year's Transcatheter Cardiovascular Therapeutics (TCT) meeting held in October in Washington, DC, is not the news per se regarding specific clinical trial results or new device technologies. Instead, it is the story behind the news. Interventional cardiology has been built on the back of evidence-based medicine. That methodology, however, has come under attack in the last year.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts